Merck stops lead PDE-4 study
Phase II development of lead phosphodiesterase-4 inhibitor compound for asthma, COPD discontinued, company announces April 25. Merck, which was developing a once-daily oral formulation under a collaborative agreement with Celltech, says it continues to study other PDE-4 inhibitor molecules for asthma and COPD, although "the timing for the development of these other molecules is not certain." Merck has demonstrated success with backup compounds where initial lead agents have failed in clinical trials - Singulair was a successor product to Venzair, Merck's first leukotrine antagonist asthma candidate whose development was halted due to clinical toxicity...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.